Cargando…

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel group of hypolipidemic drugs that are recommended particularly for high-risk hypercholesterolemia patients, including those with primary hypercholesterolemia (PH), where lifelong exposure to high low-density lipoprotein (LD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pęczek, Piotr, Leśniewski, Mateusz, Mazurek, Tomasz, Szarpak, Lukasz, Filipiak, Krzysztof J., Gąsecka, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224623/ https://www.ncbi.nlm.nih.gov/pubmed/34071103 http://dx.doi.org/10.3390/life11060466

Ejemplares similares

Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications
por: Szwed, Piotr, et al.
Publicado: (2021)

Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease
por: Rogula, Sylwester, et al.
Publicado: (2022)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
por: Basiak, Marcin, et al.
Publicado: (2022)

LDL-Cholesterol and Platelets: Insights into Their Interactions in Atherosclerosis
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment
por: Skwarek, Aleksandra, et al.
Publicado: (2021)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
por: Gąsecka, Aleksandra, et al.
Publicado: (2021)

Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding?
por: Rogula, Sylwester P., et al.
Publicado: (2020)

Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data
por: Chlebus, Krzysztof, et al.
Publicado: (2022)

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis
por: Jaguszewski, Milosz J., et al.
Publicado: (2021)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

How to Maintain Safety and Maximize the Efficacy of Cardiopulmonary Resuscitation in COVID-19 Patients: Insights from the Recent Guidelines
por: Chojecka, Dominika, et al.
Publicado: (2021)

Health-related Quality of Life Increases After First-time Acute Myocardial Infarction: a Population-based Study
por: Gąsecka, Aleksandra, et al.
Publicado: (2022)

Milrinone or dobutamine in patients with heart failure: evidence from meta‐analysis
por: Szarpak, Lukasz, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
por: Kochanowska, Anna, et al.
Publicado: (2023)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Pleiotropic Effects of Acetylsalicylic Acid after Coronary Artery Bypass Grafting—Beyond Platelet Inhibition
por: Siwik, Dominika, et al.
Publicado: (2021)

Correlation between takotsubo cardiomyopathy and SARS-CoV-2 infection
por: Szarpak, Lukasz, et al.
Publicado: (2021)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
por: Guo, Qianyun, et al.
Publicado: (2020)

Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
por: Rogula, Sylwester, et al.
Publicado: (2022)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

Levosimendan improves the acute course of takotsubo syndrome: a pooled analysis
por: Jaguszewski, Milosz J., et al.
Publicado: (2021)

A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19
por: Szarpak, Luiza, et al.
Publicado: (2021)

Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022)

The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022)

Post-COVID-19 heart syndrome
por: Gasecka, Aleksandra, et al.
Publicado: (2021)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

PCSK9 Inhibitors in a Statin-Intolerant Transgender Man With Heterozygous Familial Hypercholesterolemia: A Case Report
por: Pirazzi, Carlo, et al.
Publicado: (2019)

Use of PCSK9 Inhibitor in a Mexican Boy with Compound Heterozygous Familial Hypercholesterolemia: A Case Report
por: Ceballos-Macías, José Juan, et al.
Publicado: (2019)

MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review
por: Czajka, Pamela, et al.
Publicado: (2021)

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
por: Karatasakis, Aris, et al.
Publicado: (2017)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_msu8e1bb2ad4v4uibgp8l0l4ta